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Mitochondrial dysfunction is a key feature of multiple diseases and thus protection of this organelle 
an important therapeutic objective. The pancreatic acinar cell, which synthesises and stores 
digestive enzyme precursors, is the most abundant cell type in pancreatic tissue and considered to 
be the primary site of acute pancreatitis (AP) initiation. Early investigations by the Liverpool group 
and others discovered that precipitants of AP, including bile acids and alcohol non-oxidative 
metabolites, disrupt calcium signalling in acinar cells leading to toxicity. Sustained cytosolic calcium 
elevations raise mitochondrial matrix calcium, triggering the opening of the mitochondrial 
permeability transition pore (MPTP), which results in a loss of membrane potential and ATP 
production vital for cellular processes (Criddle et al., 2006; Mukherjee et al., 2016). The prime 
consequence of pancreatic mitochondrial dysfunction in AP is necrotic cell death, the extent of 
which is a major determinant of clinical outcome. Subsequent studies have shown that calcium-
dependent mitochondrial dysfunction in response to AP precipitants also occurs in ductal cells, 
widening the cast of players implicated in the development of AP (Hegyi & Petersen, 2013). There is 
currently no specific therapy for the disease and protection of mitochondria by MPTP inhibition is 
considered a promising therapeutic approach.  
The precise composition of the MPTP, however, remains controversial and is the subject of vigorous 
debate. Since discovery of calcium-dependent permeability transition in mitochondria many detailed 
studies been performed to establish its core components, involving genetic manipulation of 
candidate pore proteins including the voltage-dependent anion channel, adenine nucleotide 
transporter and ATP synthase. Although no firm consensus has yet been reached, it is widely 
recognised that cyclophilin D is a key modulator of MPTP opening and a prime target for drug 
development in many pathologies. With respect to AP, genetic deletion and pharmacological 
inhibition of cyclophilin D were shown to be beneficial in multiple models that reflect different 
aetiologies. Thus in vivo pathological changes in response to bile acid ductal infusion (TLCS-AP), non-
oxidative ethanol metabolites generated by fat/alcohol administration (FAEE-AP)(Huang et al., 2014) 
and caerulein hyperstimulation (CER-AP) were protected by treatment with the archetypal 
cyclophilin D inhibitor cyclosporine A, a newer derivative Debio 025 (Alisporivir; Debiopharm), and 
by cyclophilin D knockout (ppif-/-)(Mukherjee et al., 2016). 
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However, a successful translation of MPTP inhibitors to the clinic for treatment of AP has not yet 
been forthcoming. Although a licensed drug, cyclosporine A is not considered appropriate for AP 
therapy due to its immunosuppressant action via calcineurin inhibition. Furthermore, despite 
promising early preclinical results, its analogue Alisporivir has not progressed to clinical development 
for AP treatment; although in a recent clinical trial it was found to be effective as combined therapy 
against chronic hepatitis C viral (HCV) infection, serious side effects were reported. In addition, an 
MPTP inhibitor TRO40303 (Trophos) which ameliorated experimental alcoholic AP but has yet to be 
tested in clinical AP, was found to be ineffective in a clinical trial for myocardial infarction. Therefore 
there is a current, pressing need to identify and evaluate novel, potent and selective cyclophilin D 
inhibitors to protect against mitochondrial dysfunction in AP. At present pharmaceutical companies 
and academic researchers are actively engaged in drug discovery programmes to address this 
important therapeutic opportunity. 
A timely new study by Tóth and colleagues [5] has conducted a thorough investigation into the 
effects of the cyclophilin D inhibitor N-methyl-4-isoleucine cyclosporine (NIM811) in experimental 
AP. Previously beneficial actions of NIM811 have been reported in diverse pathologies, including 
ischaemic-reperfusion injury, central nervous system damage, and encephalomyelitis. Since it 
exhibited no toxic immunosuppressant activity or serious adverse effects in an HCV-infected patient 
study, potential clinical utility is indicated for diseases in which mitochondrial dysfunction is core. 
The exciting new results of Tóth et al. demonstrate promising protective actions of this compound in 
in vivo experimental AP models and in vitro isolated pancreatic cells. In ductal cells they found that 
NIM811 inhibited mitochondrial depolarisation and necrosis induced by bile acid and a fat/alcohol 
combination. Furthermore, cyclophilin D knockout (ppif-/-) was not only protective against 
mitochondrial dysfunction and necrotic cell death caused by AP precipitants in isolated pancreatic 
acinar cells, in accord with previous results (Mukherjee et al., 2016), but also in ductal cells indicating 
a combined beneficial outcome in two cell types implicated in AP progression (Hegyi & Petersen, 
2013). Importantly, oral treatment with NIM811 i.e. after AP induction, ameliorated both TLCS-AP 
and FAEE-AP in vivo, although its effects were noticeably weaker in the latter model which may 
reflect mechanistic differences relating to aetiology and therefore have implications for therapy. No 
toxic effects of NIM811 administration per se were detected in the study and a fuller evaluation of 
its clinical potential to treat AP may be warranted. 
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